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Abstract
Background: Idiopathic epilepsy (IE) is a naturally occurring and significant seizure disorder affecting all dog
breeds. Because dog breeds are genetically isolated populations, it is possible that IE is attributable to common
founders and is genetically homogenous within breeds. In humans, a number of mutations, the majority of which
are genes encoding ion channels, neurotransmitters, or their regulatory subunits, have been discovered to cause
rare, specific types of IE. It was hypothesized that there are simple genetic bases for IE in some purebred dog
breeds, specifically in Vizslas, English Springer Spaniels (ESS), Greater Swiss Mountain Dogs (GSMD), and Beagles,
and that the gene(s) responsible may, in some cases, be the same as those already discovered in humans.
Results: Candidate genes known to be involved in human epilepsy, along with selected additional genes in the
same gene families that are involved in murine epilepsy or are expressed in neural tissue, were examined in
populations of affected and unaffected dogs. Microsatellite markers in close proximity to each candidate gene
were genotyped and subjected to two-point linkage in Vizslas, and association analysis in ESS, GSMD and Beagles.
Conclusions: Most of these candidate genes were not significantly associated with IE in these four dog breeds,
while a few genes remained inconclusive. Other genes not included in this study may still be causing monogenic
IE in these breeds or, like many cases of human IE, the disease in dogs may be likewise polygenic.
Background
The prevalence of epilepsy in humans is reported to be in
the range of 4 - 10/1000 in most study settings [1], with
idiopathic epilepsy (IE) representing 15 - 20% of these
cases [2]. It is now generally accepted that IE in humans is
due to an underlying genetic origin [2], although causative
mutations have been discovered in only a small subset of
IEs, mostly in isolated populations. These identified epi-
lepsy mutations are, for the most part, Mendelian or
monogenic IEs [3-6], and are often termed “channelopa-
thies” due to their occurrence in ion channel genes. In a
recent review, 16 of 21 susceptibility genes for human epi-
l e p s yw e r ei o nc h a n n e l so rn e u r otransmitter receptors [7].
Canine epilepsy is a naturally occurring, spontaneous
condition. Canine seizures exhibit a remarkable resem-
blance to human seizures [8] and the usefulness of natu-
rally occurring canine epilepsy as a translational model to
explore potential treatments for human epilepsy was
recently proposed by Leppik, et al. [9]. The prevalence of
canine epilepsy is estimated to be between 0.5% and 5.7%
and it is the most common chronic neurological disorder
in dogs [10]. A diagnosis of IE in the canine indicates
recurrent seizures for which no cause can be identified
and implies a genetic predisposition [11]. While the mole-
cular basis of IE in canines is entirely unknown, a heredi-
tary basis for IE has been suggested in a number of dog
breeds including Beagles [12], British Alsatians [13], Kee-
shonds [14], Labrador retrievers [15], Golden retrievers
[16,17], Bernese mountain dogs [18], Belgian Tervurens
[19,20], Boxers [21], Shetland sheepdogs [22], Vizslas [23],
English Springer Spaniels [24], Irish wolfhounds [25], and
Standard Poodles [26]. One inherited progressive seizure
disorder that has been identified in dogs is the autosomal
recessive Lafora disease in Miniature Wirehaired Dachs-
hunds [27]. This progressive myoclonic epilepsy disorder
results from a mutation in the EPM2B (also known as
NHLRC1-NHL repeat containing 1) gene.
Modes of inheritance predicted from examination of
pedigrees of dogs with IE show evidence for a gene of
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which could occur due to a founder effect. Examples
include the English Springer Spaniel (partially penetrant
autosomal recessive or polygenic inheritance) [24], the
Vizsla (autosomal recessive or polygenic inheritance)
[23], and the Golden Retriever [16] and the Bernese
Mountain Dog [18] (both autosomal recessive but con-
t r o l l e db ym o r et h a no n eg e n e ) .T h e r ei se n o u g hv a r i a -
tion in mode of inheritance and clinical characteristics
in dogs to presume that the underlying genetic basis is
unlikely to be identical between breeds.
Linebreeding and inbreeding have become common-
place to meet the very specific dog breed standards of
the hundreds of dog breeds in existence today. These
practices, while creating more uniform offspring, can
also result in deleterious diseases due to the concentra-
tion of recessive mutations passed from the founders.
Almost half of the nearly four hundred genetic disorders
that have been described in dogs are recognized exclu-
sively in one or a few breeds [28], presumably due to a
strong founder effect.
The aim of the present study was to take advantage of
the likely founder effect occurring in purebred dogs
with IE in order to investigate an underlying genetic
basis for IE in four dog breeds: the Vizsla, the English
Springer Spaniel (ESS), the Greater Swiss Mountain Dog
(GSMD) and the Beagle. A candidate gene approach
was utilized; genes known to be involved in inherited
human epilepsy, along with two genes involved in
mouse epilepsy models and additional related gene
family members, were selected. Most candidate genes
tested were ion channels. Microsatellite markers within
or very close to these genes were used to generate geno-
types which were then subjected to either two-point
linkage analysis or association chi-square studies. Using
four different breeds, which may each have different
forms of IE, increased the chances of potentially finding
an associated gene in at least one of the breeds.
Results
Call rates in each sample set for the microsatellite markers
that were ultimately used in each analysis were approxi-
mately 90% or higher. Heterozygosity was recorded for
each marker as a measure of that marker’s extent of utility
for this study. Average heterozygosity ± standard error of
all markers analyzed for Beagles was 0.574 ± 0.024, for
Vizslas was 0.569 ± 0.026, for ESS was 0.425 ± 0.030, and
for GSMD was 0.341 ± 0.030. As expected, the average
heterozygosity varied by breed and markers that were
informative in one breed were not necessarily so in
another breed. Out of all tested microsatellites, there were
greater numbers of low heterozygosity (cut-off of 0.3) mar-
kers in the GSMD (27) and ESS (20) compared to the Viz-
slas (9) and Beagles (6), resulting in the lower average
heterozygosities for the GSMD and ESS. For some genes,
despite testing several microsatellites, results remain unin-
formative. For example, GABRD remains inconclusive in
the ESS, despite testing three different microsatellites.
From the list of 52 candidate genes, 20 are known to be
associated with inherited human epilepsy (indicated by a
bolded entry with * in the tables) and two are associated
with inherited mouse epilepsy models (indicated by a
bolded entry with # in the tables). All 20 of the inherited
human epilepsy-associated genes and both mouse model
genes were analyzed at least once in all four of the test
breeds, except for CHRNA2 in the Vizslas. However, not
all of the other 30 genes were examined in every breed.
In the two-point linkage study, the two large Vizsla
families were divided into ten smaller families to decrease
complexity and inbreeding loops. The power of this ten
family pedigree to detect significant linkage was demon-
strated with simulated linkage analysis. The highest aver-
age LOD score for simulated linkage was 3.63, obtained
by using a simulated marker with four alleles, no hetero-
geneity, and a recombination frequency of 0.001. The
maximum attainable LOD score in these simulations was
8.46, obtained by using a simulated marker with three
alleles, 5% heterogeneity, and a recombination frequency
of 0.001. All of the simulation combinations obtained
average LOD scores above 2.0 (suggestive linkage),
demonstrating that the pedigrees are sufficient to detect
linkage for a monogenic mutation. Results for the Vizslas
are shown in Table 1. The majority of the candidate gene
loci have very negative LOD scores and 43 genes were
successfully excluded from being linked with IE in this
breed. All of the human epilepsy-associated genes, with
the exception of CHRNA2, and both of the mouse model
genes were excluded. Four genes (CACNA1I, CACNB3,
CHRNA1,a n dSCN11A) had low heterozygosity or
monomorphism for the markers tested, therefore, these
genes cannot be excluded. In addition, two genes
(CACNB1 and CACNB2) had LOD values falling between
-2.0 and 3.2, a grey zone of being neither linked nor
unlinked; thus, conclusions cannot be drawn concerning
possible linkage of these genes to IE in Vizslas. The most
interesting of these was CACNB1,w h i c hh a daL O Do f
0.820 and a heterozygosity of 0.548.
Results for the English Springer Spaniels are shown in
Table 2. Pearson chi-square p-values are reported for this
nonparametric association study. The majority of the loci
(n = 36) had highly insignificant p-values, decreasing the
likelihood that these genes are associated with IE in this
breed; eighteen of the inherited human epilepsy genes
were in this group, as were both of the mouse epilepsy
genes. Nine genes, two of which are human epilepsy-
associated genes (GABRD and CHRNA2),h a dm a r k e r s
with heterozygosities falling below the 0.3 cut-off, prohi-
biting the drawing of conclusions about these genes. One
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Gene Name Designator H LOD at 0 cM
(10 Fam)
Results
*ARX First Set 0.555 (-)16.99 Excluded
*CACNA1A First Set 0.163 (—) Low Heterozygosity
*CACNA1A Second Set 0.180 (—) Low Heterozygosity
*CACNA1A Third Set 0.142 (—) Low Heterozygosity
*CACNA1A Fourth Set 0.659 (-)8.06 Excluded
CACNA1B First Set 0.757 (-)7.78 Excluded
CACNA1D First Set 0.725 (-)16.18 Excluded
CACNA1E First Set 0.783 (-)11.03 Excluded
CACNA1F First Set 0.655 (-)23.95 Excluded
CACNA1G First Set 0.584 (-)12.33 Excluded
*CACNA1H First Set 0.000 (—) Monomorphic
*CACNA1H Second Set 0.423 (-)7.59 Excluded
CACNA1I First Set 0.275 (—) Low Heterozygosity
#CACNA2D2 First Set 0.495 (-)1.34 Neither Linked Nor Unlinked
#CACNA2D2 Second Set 0.665 (-)6.88 Excluded
CACNB1 First Set 0.548 0.82 Neither Linked Nor Unlinked
CACNB2 First Set 0.670 (-)1.39 Neither Linked Nor Unlinked
CACNB3 First Set 0.203 (—) Low Heterozygosity
*CACNB4 First Set 0.781 (-)6.08 Excluded
#CACNG2 First Set 0.739 (-)21.61 Excluded
CACNG3 First Set 0.628 (-)10.69 Excluded
CACNG4 First Set 0.615 (-)8.70 Excluded
CACNG6 First Set 0.530 (-)8.35 Excluded
CHRNA1 First Set 0.291 (—) Low Heterozygosity
CHRNA3 First Set 0.629 (-)3.58 Excluded
*CHRNA4 and KCNQ2 See KCNQ2
CHRNA7 First Set 0.695 (-)9.65 Excluded
CHRNA9 First Set 0.420 (-)4.54 Excluded
CHRNA10 First Set 0.795 (-)6.43 Excluded
CHRNB1 First Set 0.587 (-)4.62 Excluded
*CHRNB2 First Set 0.725 (-)18.39 Excluded
CHRND First Set 0.655 (-)5.05 Excluded
*CLCN2 First Set 0.665 (-)4.75 Excluded
DNM1 First Set 0.495 (-)3.63 Excluded
DNM1 Fourth Set 0.355 (-)3.77 Excluded
DNM1 Fifth Set 0.677 (-)3.93 Excluded
*GABRA1 First Set 0.605 (-)6.12 Excluded
GABRA2 First Set 0.575 (-)20.25 Excluded
GABRA6 First Set 0.646 (-)10.69 Excluded
*GABRD First Set 0.745 (-)3.73 Excluded
*GABRG2 First Set 0.773 (-)22.33 Excluded
*GABRG2 Second Set 0.455 (-)4.39 Excluded
*KCNA1 First Set 0.716 (-)6.71 Excluded
KCNQ1 First Set 0.495 (-)3.10 Excluded
*KCNQ2 and CHRNA4 Second Set 0.578 (-)1.50 Neither Linked Nor Unlinked
*KCNQ2 and CHRNA4 Third Set 0.526 (-)0.49 Neither Linked Nor Unlinked
*KCNQ2 and CHRNA4 Fourth Set 0.676 (-)11.37 Excluded
*KCNQ3 First Set 0.711 (-)2.01 Excluded
KCNQ5 First Set 0.535 (-)5.29 Excluded
*LGI1 First Set 0.725 (-)9.89 Excluded
*ME2 First Set 0.625 (-)7.89 Excluded
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gene, initially resulted in marginally significant p-values
for two different microsatellites: 0.074 (first set) and
0.033 (second set), however, a third microsatellite’s alleles
resulted in an insignificant p-value of 0.890. Additionally,
when the Bonferroni correction was applied, these results
were not significant; therefore, no further follow-up was
initiated.
Results for the Greater Swiss Mountain Dogs are
shown in Table 3. As with the ESS, Pearson chi-square
p-values are reported for this association study. Again,
the majority of the loci (n = 35) had highly insignificant
p-values and are unlikely to be associated with IE in the
GSMD; this included 17 of the 20 inherited human epi-
lepsy-associated genes and both of the mouse model
genes. This breed had the lowest overall average hetero-
zygosity and results for eleven genes, three of which are
human epilepsy-associated (GABRD, KCNA1, and ME2),
could not be determined due to low heterozygosity. The
first marker analyzed for KCND2 resulted in a p-value
of 0.036, prompting the examination of two additional
markers. One of these was uninformative, but the other
had a heterozygosity of 0.729 and a p-value of 0.155,
rendering this gene not significant and unlikely to be
associated to IE in GSMD. Additionally, CHRNB2,a
gene that is associated with human epilepsy, resulted in
a p-value of 0.055. While this p-value is potentially sug-
gestive of association, when correcting for multiple test-
ing with the Bonferroni correction, it does not approach
significance.
Results for the Beagles are shown in Table 4. In this
breed association study, highly insignificant p-values for
43 candidate genes indicate that these genes are likely
not associated with IE in Beagles. All twenty of the
inherited human epilepsy-associated genes and both of
the mouse model genes had insignificant p-values in
this breed. Only three genes (CACNA1D, CACNG3, and
KCNQ5) were inconclusive due to low heterozygosity in
this breed. CHRNA1 gave a p-value of 0.05 on its initial
marker, leading to the development of primers for
additional microsatellites. Two of these, CHRNA1’s third
set and fourth set of primers, gave p-values of 0.072 and
0.056, respectively, but CHRNA1’s second set of primers
resulted in a highly insignificant p-value of 0.600, mak-
ing it unlikely that this locus is associated with IE in
this breed. Two other loci, both human epilepsy-asso-
ciated genes, though insignificant, had lower p-values:
KCNQ3 at 0.077 and LGI1 at 0.070. Again, applying cor-
rection for multiple testing indicates that these p-values
are not significant.
Discussion
This study was designed to use LD to exploit a possible
founder effect suspected to be responsible for IE in
these breeds by testing as many candidate genes as pos-
sible using microsatellite markers. Microsatellites have
been shown to be a practical and useful tool in candi-
date gene studies [29]. Marker locations were selected
within average blocks of canine LD so that one marker’s
result could, in theory, accurately represent the entire
gene. The use of multiple breeds allowed for the possi-
bility of assessing whether a discovered mutation was
unique to one breed, suggesting the suspected founder
effect specific to that breed, or was observed in several
breeds, indicating a much older mutation. While no
mutations were identified to draw definitive conclusions,
it is not unreasonable to speculate that in dogs the
underlying genetic basis of IE may vary by breed, as it is
known that the rare human monogenic IEs are typically
isolated by family [30-35]. These experiments incorpo-
rated both linkage analysis and association analysis, each
having different strengths. While linkage analysis is the
more powerful of these two statistical analysis methods
for detecting Mendelian disease mutations, it requires
samples from appropriate family structures. Conversely,
association analysis does not require family-based sam-
ples, and it is generally considered more powerful than
linkage analysis in detecting polygenic disease associa-
tions. Sequencing of the subset of human IE-associated
candidate genes was not pursued for this study, as brain
Table 1 Vizsla two-point linkage analysis results (Continued)
*NHLRC1 Second Set 0.509 (-)8.49 Excluded
*SCN1A First Set 0.600 (-)7.83 Excluded
*SCN1B First Set 0.820 (-)8.52 Excluded
*SCN2A First Set 0.833 (-)13.95 Excluded
SCN3A First Set 0.000 (—) Monomorphic
SCN3A Second Set 0.545 (-)5.82 Excluded
SCN3B First Set 0.751 (-)21.76 Excluded
SCN8A First Set 0.805 (-)18.57 Excluded
SCN11A First Set 0.255 (—) Low Heterozygosity
Bolded genes marked with a * indicate those associated with human IE, and bolded genes marked with a # indicate those associated with mouse models of
epilepsy. The breed cohort was assembled and statistics were performed as described in Materials and Methods. “Designator” indicates each set of primers, first,
second, etc., designed for that gene and used in this breed (See Additional files 1 and 2). H = heterozygosity of the marker.
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results
Gene Name Designator H Chi
Square
P-Value
Results
*ARX First Set 0.485 0.843 Not Significant
*CACNA1A First Set 0.312 0.308 Not Significant
CACNA1B First Set 0.062 (—) Low
Heterozygosity
CACNA1D First Set 0.000 (—) Monomorphic
CACNA1E First Set 0.684 0.314 Not Significant
CACNA1F First Set 0.454 0.097 Not Significant
CACNA1G First Set 0.467 0.916 Not Significant
*CACNA1H First Set 0.734 0.644 Not Significant
CACNA1I First Set 0.546 0.135 Not Significant
#CACNA2D2 First Set 0.369 0.898 Not Significant
CACNB1 First Set 0.734 0.744 Not Significant
CACNB2 First Set 0.619 0.305 Not Significant
CACNB3 First Set 0.362 0.113 Not Significant
*CACNB4 First Set 0.830 0.989 Not Significant
#CACNG2 First Set 0.413 0.963 Not Significant
CACNG3 First Set 0.653 0.130 Not Significant
CACNG4 First Set 0.635 0.220 Not Significant
CACNG6 First Set 0.561 0.267 Not Significant
CHRNA1 First Set 0.538 0.249 Not Significant
*CHRNA2 First Set 0.233 (—) Low
Heterozygosity
*CHRNA4 and
KCNQ2
See KCNQ2
CHRNA5 First Set 0.436 0.788 Not Significant
CHRNA7 First Set 0.692 0.622 Not Significant
CHRNA9 First Set 0.259 (—) Low
Heterozygosity
CHRNB1 First Set 0.207 (—) Low
Heterozygosity
*CHRNB2 First Set 0.173 (—) Low
Heterozygosity
*CHRNB2 Second Set 0.198 (—) Low
Heterozygosity
*CHRNB2 Third Set 0.321 0.982 Not Significant
*CLCN2 First Set 0.492 0.719 Not Significant
DNM1 First Set 0.227 (—) Low
Heterozygosity
DNM1 Second Set 0.528 0.886 Not Significant
DNM1 Third Set 0.700 0.598 Not Significant
DNM1 Fourth Set 0.714 0.875 Not Significant
DNM1 Fifth Set 0.618 0.853 Not Significant
*GABRA1 First Set 0.416 0.074 Inconclusive
*GABRA1 Second Set 0.490 0.033 Inconclusive
*GABRA1 Third Set 0.369 0.890 Not Significant
*GABRD First Set 0.257 (—) Low
Heterozygosity
*GABRD Second Set 0.223 (—) Low
Heterozygosity
*GABRD Third Set 0.295 (—) Low
Heterozygosity
*GABRG2 First Set 0.663 0.443 Not Significant
Table 2 English Springer Spaniel association chi-square
results (Continued)
*KCNA1 First Set 0.587 0.965 Not Significant
KCND2 First Set 0.233 (—) Low
Heterozygosity
*KCNQ2 and
CHRNA4
Second Set 0.738 0.710 Not Significant
*KCNQ3 First Set 0.541 0.474 Not Significant
KCNQ5 First Set 0.206 (—) Low
Heterozygosity
*LGI1 First Set 0.641 0.834 Not Significant
*ME2 First Set 0.492 0.619 Not Significant
*NHLRC1 Second Set 0.684 0.784 Not Significant
*SCN1A First Set 0.199 (—) Low
Heterozygosity
*SCN1A Second Set 0.082 (—) Low
Heterozygosity
*SCN1A Third Set 0.211 (—) Low
Heterozygosity
*SCN1A Fourth Set 0.337 0.968 Not Significant
*SCN1B First Set 0.676 0.216 Not Significant
*SCN2A First Set 0.766 0.670 Not Significant
SCN3A First Set 0.000 (—) Monomorphic
SCN3A Second Set 0.069 (—) Low
Heterozygosity
SCN3B First Set 0.563 0.834 Not Significant
SCN8A First Set 0.070 (—) Low
Heterozygosity
SCN8A Second Set 0.000 (–) Monomorphic
SCN11A First Set 0.637 0.396 Not Significant
Bolded genes marked with a * indicate those associated with human IE, and
bolded genes marked with a # indicate those associated with mouse models
of epilepsy. The breed cohort was assembled and statistics were performed as
described in Materials and Methods. “Designator” indicates each set of
primers, first, second, etc., designed for that gene and used in this breed (See
Additional files 1 and 2). H = heterozygosity of the marker.
Table 3 Greater Swiss Mountain Dog association chi-
square results
Gene Name Designator H Chi
Square
P-Value
Results
*ARX First Set 0.396 0.606 Not Significant
*CACNA1A First Set 0.000 (—) Monomorphic
*CACNA1A Second Set 0.408 0.740 Not Significant
CACNA1B First Set 0.370 0.905 Not Significant
CACNA1D First Set 0.699 0.529 Not Significant
CACNA1E First Set 0.675 0.953 Not Significant
CACNA1F First Set 0.106 (—) Low
Heterozygosity
CACNA1G First Set 0.000 (—) Monomorphic
CACNA1G Second Set 0.023 (—) Low
Heterozygosity
*CACNA1H First Set 0.000 (—) Monomorphic
*CACNA1H Second Set 0.517 0.272 Not Significant
CACNA1I First Set 0.483 0.449 Not Significant
#CACNA2D2 First Set 0.308 0.442 Not Significant
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Page 5 of 14Table 3 Greater Swiss Mountain Dog association chi-
square results (Continued)
CACNB1 First Set 0.261 (—) Low
Heterozygosity
CACNB2 First Set 0.000 (—) Monomorphic
CACNB3 First Set 0.322 0.718 Not Significant
*CACNB4 First Set 0.628 0.709 Not Significant
#CACNG2 First Set 0.690 0.382 Not Significant
CACNG3 First Set 0.000 (—) Monomorphic
CACNG3 Second Set 0.591 0.527 Not Significant
CACNG4 First Set 0.298 (—) Low
Heterozygosity
CACNG6 First Set 0.482 0.323 Not Significant
CHRNA1 First Set 0.491 0.730 Not Significant
CHRNA1 Second Set 0.670 0.256 Not Significant
CHRNA1 Third Set 0.656 0.374 Not Significant
CHRNA1 Fourth Set 0.452 0.582 Not Significant
*CHRNA2 First Set 0.461 0.644 Not Significant
*CHRNA4 and
KCNQ2
See KCNQ2
CHRNA5 First Set 0.389 0.483 Not Significant
CHRNA7 First Set 0.810 0.924 Not Significant
CHRNA9 First Set 0.615 0.875 Not Significant
CHRNB1 First Set 0.000 (—) Monomorphic
*CHRNB2 First Set 0.333 0.055 Not Significant
*CLCN2 First Set 0.519 0.600 Not Significant
DNM1 First Set 0.139 (—) Low
Heterozygosity
DNM1 Second Set 0.364 0.799 Not Significant
DNM1 Third Set 0.500 0.834 Not Significant
DNM1 Fourth Set 0.000 (—) Monomorphic
DNM1 Fifth Set 0.484 0.464 Not Significant
*GABRA1 First Set 0.549 0.354 Not Significant
*GABRD First Set 0.088 (—) Low
Heterozygosity
*GABRD Second Set 0.088 (—) Low
Heterozygosity
*GABRD Third Set 0.081 (—) Low
Heterozygosity
*GABRG2 First Set 0.219 (—) Low
Heterozygosity
*GABRG2 Second Set 0.458 0.929 Not Significant
*KCNA1 First Set 0.171 (—) Low
Heterozygosity
KCND2 First Set 0.480 0.036 Inconclusive
KCND2 Second Set 0.729 0.155 Not Significant
KCND2 Third Set 0.124 (—) Low
Heterozygosity
*KCNQ2 and
CHRNA4
First Set 0.441 0.677 Not Significant
*KCNQ3 First Set 0.382 0.904 Not Significant
KCNQ5 First Set 0.100 (—) Low
Heterozygosity
*LGI1 First Set 0.440 0.244 Not Significant
*ME2 First Set 0.219 (—) Low
Heterozygosity
*NHLRC1 Second Set 0.405 0.240 Not Significant
Table 3 Greater Swiss Mountain Dog association chi-
square results (Continued)
*SCN1A First Set 0.749 0.706 Not Significant
*SCN1B First Set 0.000 (—) Monomorphic
*SCN1B Second Set 0.000 (—) Monomorphic
*SCN1B Third Set 0.026 (—) Low
Heterozygosity
*SCN1B Fourth Set 0.485 0.233 Not Significant
*SCN2A First Set 0.686 0.767 Not Significant
SCN3A First Set 0.000 (—) Monomorphic
SCN3A Second Set 0.437 0.378 Not Significant
SCN3B First Set 0.000 (—) Monomorphic
SCN3B Second Set 0.000 (—) Monomorphic
SCN8A First Set 0.152 (—) Low
Heterozygosity
SCN8A Second Set 0.576 0.996 Not Significant
SCN11A First Set 0.597 0.967 Not Significant
Bolded genes marked with a * indicate those associated with human IE, and
bolded genes marked with a # indicate those associated with mouse models
of epilepsy. The breed cohort was assembled and statistics were performed as
described in Materials and Methods. “Designator” indicates each set of
primers, first, second, etc., designed for that gene and used in this breed (See
Additional files 1 and 2). H = heterozygosity of the marker.
Table 4 Beagle association chi-square results
Gene Name Designator H Chi
Square
P-Value
Results
*ARX First Set 0.508 0.643 Not Significant
*CACNA1A First Set 0.636 0.813 Not Significant
CACNA1B First Set 0.836 0.765 Not Significant
CACNA1D First Set 0.123 (—) Low
Heterozygosity
CACNA1E First Set 0.697 0.254 Not Significant
CACNA1F First Set 0.671 0.578 Not Significant
CACNA1G First Set 0.640 0.092 Not Significant
*CACNA1H Second Set 0.344 0.873 Not Significant
CACNA1I First Set 0.570 0.365 Not Significant
#CACNA2D2 First Set 0.438 0.917 Not Significant
CACNB1 First Set 0.318 0.661 Not Significant
CACNB2 First Set 0.612 0.577 Not Significant
CACNB3 First Set 0.577 0.148 Not Significant
*CACNB4 First Set 0.864 0.753 Not Significant
#CACNG2 First Set 0.720 0.502 Not Significant
CACNG3 First Set 0.135 (—) Low
Heterozygosity
CACNG4 First Set 0.633 0.816 Not Significant
CACNG6 First Set 0.505 0.413 Not Significant
CHRNA1 First Set 0.686 0.050 Not Significant
CHRNA1 Second Set 0.506 0.600 Not Significant
CHRNA1 Third Set 0.661 0.072 Not Significant
CHRNA1 Fourth Set 0.790 0.056 Not Significant
*CHRNA2 First Set 0.664 0.590 Not Significant
*CHRNA4 and
KCNQ2
See KCNQ2
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Page 6 of 14tissues for obtaining cDNAs for most cost efficient
sequencing were not available.
Overall marker informativeness was highly influenced
by sample population. The Vizslas and Beagles had
excellent average heterozygosities (0.569 and 0.574,
respectively), while the ESS and GSMD were much
lower (0.425 and 0.341, respectively). This may be due,
in part, to the sample cohorts: the ESS and GSMD were
s e tu pa sd i s c o r d a n tf u l l -o rhalf-sibling pairs, whereas
the Vizslas were constructed as large pedigrees, and the
Beagles were case/control matched pairs that did not
share common ancestors to at least the grandparent
level. Reduced marker heterozygosity across breeds
could also be influenced by a higher degree of inbreed-
ing within the ESS and GSMD sample cohorts in this
study, and the lower average heterozygosities of these
two breeds may suggest a founder effect that could
eventually help uncover associations. However, marker
informativeness is not entirely dependent on sample
population, as evidenced by CACNA1A, which was poly-
morphic enough to be confidently insignificant after
analyzing one or two microsatellites in ESS, GSMD, and
Beagles, but remained inconclusive through three mar-
kers in the Vizslas and ultimately required a fourth
microsatellite to achieve a suitable heterozygosity in this
breed. The accepted marker heterozygosity of 0.3 is per-
haps low, especially when analyzing only a single micro-
satellite for each candidate gene, however, for many of
the insignificant microsatellite results in all four breeds
the heterozygosity was > 0.5.
Ultimately, 16 of the 20 human epilepsy-associated can-
didate genes (ARX, CACNA1A, CACNA1H, CACNB4,
CHRNA4, CHRNB2, CLCN2, GABRA1, GABRG2,
KCNQ2, KCNQ3, LGI1, NHLRC1, SCN1A, SCN1B,a n d
SCN2A) and both of the mouse model genes (CACNA2D2
and CACNG2) were either excluded (with linkage) or
demonstrated insignificant association to IE in all four of
the breed cohorts. Another two of them (KCNA1 and
ME2) were insignificant in three out of four breed cohorts,
remaining inconclusive only in the GSMD. One gene,
GABRD, was inconclusive in two breeds (ESS and GSMD),
and CHRNA2 was inconclusive in ESS and was not tested
in Vizslas. Insignificant association to IE was demonstrated
in most of the additional candidate genes tested. For every
breed, however, there were a handful of markers that were
inconclusive, due to low heterozygosity.
The few markers with potentially interesting results
(uncorrected p-values of < 0.05) that were not excluded
by follow-up markers, including CACNB1 in the Vizsla,
CHRNB2 in the GSMD, and KCNQ3 and LGI1 in the
Beagle, were of minimal interest when correcting for
multiple testing. With the Bonferroni correction, a
p-value of 0.05 considered as statistically significant
would be lowered to 0.0025 for twenty tests, and further
lowered to 0.00125 for forty tests; p-values of this magni-
tude were not obtained for any marker, and all breeds
were tested on more than forty genes. The potential of
false positives due to population stratification must also
be considered for these few genes with suggestive results
in the association studies, despite attempts to control for
the degree of relatedness. Haplotype association analysis
was not possible with this data since there were not
Table 4 Beagle association chi-square results (Continued)
CHRNA7 First Set 0.741 0.513 Not Significant
CHRNA9 First Set 0.665 0.694 Not Significant
CHRNB1 First Set 0.491 0.555 Not Significant
*CHRNB2 First Set 0.583 0.885 Not Significant
*CLCN2 First Set 0.762 0.577 Not Significant
DNM1 First Set 0.278 (—) Low
Heterozygosity
DNM1 Second Set 0.386 0.693 Not Significant
DNM1 Third Set 0.588 0.314 Not Significant
DNM1 Fourth Set 0.565 0.953 Not Significant
DNM1 Fifth Set 0.563 0.430 Not Significant
*GABRA1 First Set 0.523 0.345 Not Significant
GABRA2 First Set 0.502 0.265 Not Significant
GABRA6 First Set 0.575 0.266 Not Significant
*GABRD First Set 0.684 0.554 Not Significant
*GABRG2 First Set 0.748 0.292 Not Significant
*GABRG2 Second Set 0.447 0.849 Not Significant
*KCNA1 First Set 0.758 0.356 Not Significant
KCND2 First Set 0.530 0.919 Not Significant
KCND2 Second Set 0.706 0.698 Not Significant
KCND2 Third Set 0.728 0.455 Not Significant
*KCNQ2 and
CHRNA4
Second Set 0.805 0.627 Not Significant
*KCNQ3 First Set 0.655 0.077 Not Significant
KCNQ5 First Set 0.106 (—) Low
Heterozygosity
*LGI1 First Set 0.234 (—) Low
Heterozygosity
*LGI1 Second Set 0.708 0.070 Not Significant
*ME2 First Set 0.585 0.282 Not Significant
*NHLRC1 First Set 0.605 0.739 Not Significant
*SCN1A First Set 0.118 (—) Low
Heterozygosity
*SCN1A Third Set 0.328 0.551 Not Significant
*SCN1B First Set 0.679 0.425 Not Significant
*SCN1B Second Set 0.649 0.885 Not Significant
*SCN2A First Set 0.680 0.763 Not Significant
SCN3B First Set 0.750 0.127 Not Significant
SCN8A First Set 0.730 0.110 Not Significant
SCN11A First Set 0.689 0.572 Not Significant
Bolded genes marked with a * indicate those associated with human IE, and
bolded genes marked with a # indicate those associated with mouse models
of epilepsy. The breed cohort was assembled and statistics were performed as
described in Materials and Methods. “Designator” indicates each set of
primers, first, second, etc., designed for that gene and used in this breed (See
Additional files 1 and 2). H = heterozygosity of the marker.
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Conclusive confirmation or exclusion of these loci can be
performed in the future with newer technologies such as
whole-genome SNP arrays, which can generate vast
amounts of data in less time.
It is possible that the populations tested were underpow-
ered to detect association if it existed. Utilizing a sibling-
pair case-control design could decrease power because the
control dog may also carry the risk allele. However, this
situation is difficult to avoid in highly inbred dog popula-
tions, and the sibling-pair case-control design should aid
in avoiding population stratification, which can create false
positive results. Although sample size requirements for
canine association studies have not been precisely defined,
based on average linkage disequilibrium estimates in dog
breeds, a starting point of approximately 25 cases and
25 controls appears to be adequate to find statistical signif-
icance for a completely penetrant recessive trait [36]. The
number increases to approximately 50 cases and 50 con-
trols when a trait is dominant, and for more complex traits
as many as 100 dogs in each group may be necessary.
Therefore, it is possible that there were not adequate num-
bers of dogs in the association studies, particularly if IE is
not monogenic. A meta-analysis might improve power by
pooling data from the three association study breeds (ESS,
GSMD, and Beagle). However, this proved to be impracti-
cal because 1) many microsatellites had varying informa-
tiveness in each breed, so that pooling data would only
work for a single microsatellite that was informative for a
gene in all three breeds and 2) microsatellites by their very
nature are highly polymorphic and there was often little
overlap in alleles between breeds. Lastly, if IE has a differ-
ent genetic basis in each of these breeds, pooling data
across breeds seems unlikely to yield interesting results.
In the linkage analysis of Vizsla pedigrees, it is possi-
b l et oc o n c l u d et h a tt h e s ec a n d i d a t eg e n el o c ia r et r u l y
excluded, due to convincingly negative LOD scores at
zero centiMorgans. However, if the inheritance and age
dependent penetrance assumptions for the Vizsla model
are incorrect, then the present linkage study is flawed.
These input assumptions were based on previous study
of IE in this breed [23] and on the best information
available. Conversely, in the association studies of the
other three breeds, it is not possible to specifically state
that the loci are “excluded”, as there is some degree of
doubt that one microsatellite marker is adequate to pro-
vide convincing evidence for exclusion of a locus with
this type of study. The addition of more markers would
help to verify these insignificant results and truly
exclude a locus. That work is beyond the scope of this
study and is better addressed with whole-genome SNP
analysis. The latest commercial canine SNP array, with
over 170,000 SNPs, became available well after these
studies were initiated. Further, the excluded and
insignificant genes reported in the present study may
only reflect the specific breeds examined, or even lines
within these breeds, and results should not necessarily
be extrapolated to other breeds.
It is possible that canine IE, like the majority of
human IE, is a genetically complex disease in most
breeds and that multiple loci contribute to susceptibility
in any given breed. The present study would very likely
have detected a major contributing locus, and it is unli-
kely that a truly causative locus is being excluded as a
false negative. In humans, the vast majority of IE
remains genetically unexplained and is considered to be
polygenic [37-39]. A recent study by Oberbauer et al.
[40] utilized microsatellites in a genome-wide linkage
scan for epilepsy loci in the Belgian shepherd dog and
concluded that the disease was highly polygenic, report-
ing a tentative six QTLs. These results further support
the conclusion that canine IE is a more complex disease
than originally hypothesized. Whole-genome association
analyses with SNP arrays are likely the platform of
choice for further studies of IE, as they can query tens
of thousands of markers simultaneously across the gen-
ome and are better able to identify multiple susceptibil-
ity loci. Additionally, copy number variants (CNVs) have
been increasingly shown to be involved in neurologic
disorders such as autism [41,42] and schizophrenia
[43,44], as well as epilepsy [45]. CNV studies of canine
epilepsy may reveal this as a similar mechanism for dis-
ease in both species.
Ultimately, canine IE found to be significantly asso-
ciated with DNA markers or with a mutation in a specific
gene would allow genetic tests to be developed to assist
dog breeders with decreasing the incidence of this dis-
ease. This would be most effective for monogenic, highly
penetrant forms of IE, but if the disease proves to be
genetically complex, with multiple genes contributing
and less than 100% penetrance, then such a test could
s t i l lp o s s i b l yb eu s e dt op r o v i d ear e l a t i v er i s kf o rI E
development within a breed. In any event, discovery of IE
associated gene loci in dogs may not only improve the
understanding of canine health, but could advance the
study of neurobiology and human health as well.
Conclusions
The present study did not identify any obvious associa-
tion or linkage between IE and the microsatellite mar-
kers tested for the various candidate genes in any of the
four dog breeds. It is possible that IE may in fact be a
polygenic disorder even in highly inbred dog breeds,
which underscores the challenging nature of investigat-
ing inherited epilepsy. Eventually identifying the genetic
causes for IE in dogs would have a significant impact on
canine health, as well as providing a useful model for IE
in humans.
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Case Definition
Since seizure activity can result from numerous discern-
able abnormalities, and only dogs very likely to be
affected with IE were to be included in the study, the
case definition was designed to eliminate, as much as
possible, all other likely causes of seizures. Therefore, in
order to qualify for “case” status for IE, each affected
dog must have had two or more seizures with clinical
normalcy between episodes, a veterinarian-administered
normal physical examination and neurological examina-
tion, as well as normal bloodwork, including a complete
b l o o dc o u n ta n db l o o dc h e m istry profile, and, when
possible, a bile acids assay. Since IE has been shown to
be statistically much more probable when the dog is
aged 1 to 5 years at the time of its first seizure [46],
only dogs whose first seizure occurred during this time
frame were included. If seizures started prior to 1 year
of age or after 5 years of age, extra criteria were then
required to enroll a dog, including a normal MRI or
CT, and/or normal CSF analysis. EEG was not used as a
case criterion due to its limited availability in clinical
veterinary practice. To be classified as unaffected, the
dog must have reached at least five years of age and be
completely free of known seizure activity. In the situa-
tion where a case was identified at a young age, and its
full- or half-sibling was used as a control, the dogs were
followed for years until the unaffected dog had reached
at least five years of age.
Dogs in these studies were privately owned and volun-
tarily enrolled by their owners with informed consent.
Cases were solicited through breed publications, presen-
tations at local and national breed club meetings, and
word of mouth. For each enrolled dog, a general health
survey, a signed owner consent form, and up to ten mLs
of whole blood in an EDTA tube were required. Blood
samples were obtained via venipuncture either at the
dog’s regular veterinarian or at specially-organized
blood-draws at breed shows across the USA. This study
was approved by the University of Minnesota IACUC.
Owners of dogs affected with seizures were asked to
fill out an additional questionnaire which asked for
information about the dog’s seizure characteristics, pre-
ictal and postictal signs, previous medical history, and
any anti-epileptic drug therapy; these were submitted by
phone, fax, postal mail or e-mail. Any additional follow-
up questions were conducted via telephone interview.
Finally, medical records for each affected dog were
obtained from the dog’s regular veterinarian and any
specialists (if applicable); these were inspected for blood-
work results and the veterinarian’s physical and neurolo-
gical examination findings. Dogs were assigned case,
control, or unknown status after careful evaluation of
this information. “Unknown” status was reserved for
those dogs displaying suspicious seizure or seizure-like
activity, but couldn’t be classified as a case for various
reasons; for example, if the dog had only one recorded
seizure or had suffered head trauma prior to onset of
the first seizure.
DNA Isolation
DNA was isolated from whole blood following standard
protocols, utilizing the Puregene DNA Isolation Kit
from Qiagen Inc. (Valencia, CA).
Breed Cohorts
Cohorts of affected and unaffected dogs for genotyping
were assembled for each of the four test breeds - the
Vizsla, the GSMD, the ESS, and the Beagle. Ultimately,
the available samples determined what type of genetic
analysis was conducted for each breed.
Vizslas
For Vizslas, the depth of the available DNA samples
from multiple siblings, parents, and many grandparents
allowed the development of multi-generation pedigrees
(Figure 1 and Figure 2) suitable for genetic linkage ana-
lysis. 96 dogs were included: 31 affected dogs, 60 unaf-
fected dogs, and 5 dogs with unknown phenotype status.
These dogs were separated into two large family pedi-
grees shown in Figures 1 and 2, and were subsequently
broken into ten smaller families to decrease inbreeding
loops for linkage analysis and calculation of LOD scores.
Greater Swiss Mountain Dogs
For the GSMD, discordant full-sibling or half-sibling
pairs of affected (n = 24) and unaffected (n = 24) dogs
were assembled and used in association studies. Siblings
were used to help avoid spurious association from popu-
lation stratification. In a few instances, two different
pairs of siblings were related to each other, such as
sharing one parent.
English Springer Spaniels
Similar to the GSMD, the ESS were assembled into dis-
cordant full- or half-sibling pairs of affected (n = 24)
and unaffected (n = 24) dogs and were used in associa-
tion studies. As in the GSMD, occasionally the pairs of
siblings were also related to one another; this was
impossible to avoid due to the inbred nature of the
breed.
Beagles
Association studies were also conducted for the Beagles.
Due to lack of available sibling pairs, pedigree analyses
were used to ensure that only dogs with no common
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Figure 1 Vizsla linkage family 1 pedigree. Pedigree of Vizsla family 1. Squares and circles represent males and females, respectively. Filled
shapes represent cases; those with question marks represent unknown phenotype status. Dogs with arrows were genotyped in this study. The
dog marked with an arrow and a + is included on both families 1 & 2, effectively making this one very large family. The Vizsla pedigrees were
broken into ten smaller families to decrease inbreeding loops before being analyzed in linkage analysis. Three dogs representing one of the ten
sub-families are not shown on either pedigree.
?
Figure 2 Vizsla linkage family 2 pedigree. Pedigree of Vizsla family 2. Squares and circles represent males and females, respectively. Filled
shapes represent cases; those with question marks represent unknown phenotype status. Dogs with arrows were genotyped in this study. The
dog marked with an arrow and a + is included on both families 1 & 2, effectively making this one very large family. The Vizsla pedigrees were
broken into ten smaller families to decrease inbreeding loops before being analyzed in linkage analysis. Three dogs representing one of the ten
sub-families are not shown on either pedigree.
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shown to be adequate for canine genetic mutation
detection [47]. Twenty-four affected dogs and 24 unaf-
fected dogs were selected for this dataset.
Candidate Gene Selection
A non-exhaustive list of candidate genes known to be
involved with inherited human epilepsy was assembled,
including potassium channels KCNA1, KCNQ2,a n d
KCNQ3; calcium channels CACNA1A, CACNA1H,a n d
CACNB4; sodium channels SCN1A, SCN2A,a n dSCN1B;
GABA receptors GABRA1, GABRD,a n dGABRG2; acet-
ylcholine receptors CHRNA2, CHRNA4,a n dCHRNB2;
and chloride channel CLCN2; as well as novel (ie, non-
ion channel and non-neurotransmitter receptor) genes
malic enzyme 2 (ME2), leucine-rich glioma inactivated 1
(LGI1), NHL repeat containing 1 (NHLRC1), and arista-
less related homeobox (ARX), for a total of 20 human
epilepsy-associated genes [30,48-54]. Two candidate
genes associated with mouse epilepsy models were also
included: CACNA2D2, (the ducky mouse) [55] and
CACNG2 (the stargazer mouse) [56].
In addition to this core set of genes, further genes
were selected from the same gene families based on
their presence in neural tissue, including: calcium chan-
nels CACNA1B, CACNA1D, CACNA1E, CACNA1F,
CACNA1G, CACNA1I, CACNB1, CACNB2, CACNB3,
CACNG3, CACNG4,a n dCACNG6;s o d i u mc h a n n e l s
SCN3A, SCN3B, SCN8A,a n dSCN11A; GABA receptors
GABRA2,a n dGABRA6; acetylcholine receptors
CHRNA1, CHRNA3, CHRNA5, CHRNA9, CHRNA10,
CHRNB1,a n dCHRND as well as CHRNA7, which has
had suggested linkage with human IE [57]; and potas-
sium channels KCND2, KCNQ1,a n dKCNQ5.F i n a l l y ,
the dynamin-1 gene (DNM1) was also examined. This
gene was recently found to be mutated in the canine
disease termed exercise induced collapse [58] and a
mutation in dynamin-1 has recently been characterized
in the fitful mouse model, wherein heterozygotes for the
mutation experience recurrent seizures and homozy-
gotes for the mutation often have lethal seizures and
other neurosensory deficits [59]. Therefore, a total of 52
candidate genes were chosen for this study.
Primer design, PCR, and Genotyping
Human mRNA sequence was obtained for each gene
from the National Center for Biotechnology Information
[ 6 0 ] .T h i ss e q u e n c ew a sB L A T e do nt h eU n i v e r s i t yo f
California - Santa Cruz Genome Browser website [61]
against the May 2005 dog genome assembly to identify
t h er e s u l t a n tg e n o m i cp o s i t i o no fe a c hg e n ei nt h ed o g .
Microsatellites were selected either within the gene or
closely flanking the gene utilizing the Variation and
Repeat - Microsatellite feature of this browser. After
capturing the microsatellite’s flanking sequence, primer
pairs to amplify each microsatellite were designed using
Primer3 [62]. An additional 5’ tail sequence was added
to each right (reverse) primer [63] to generate fluores-
cent labels in PCR. All primer sequences are shown in
Additional file 1, and Additional file 2 lists the Mb posi-
tions of each gene and microsatellite. Every attempt was
made to select microsatellites less than 1 Mb distant
from the gene, in order to remain within estimated
blocks of canine linkage disequilibrium (LD) [36] for
each gene. LD is the non-random association of alleles
at two loci and, within dog breeds, can extend over dis-
tances of several megabases [36]. However, for many of
the candidate genes, several microsatellites (and there-
fore several sets of primers) needed to be tested due to
the microsatellite’s lack of informativeness (mono-
morphism or low heterozygosity), and eventually the
only useable microsatellite was located further away.
Additional file 2 indicates which microsatellites (n = 3)
were >1 Mb distant. CHRNA4 and KCNQ2 were close
enough to one another in the canine genome that one
marker was used for both genes.
Each microsatellite was PCR amplified in 15-μL reac-
tions including 12.5 ng canine DNA, 10X PCR Buffer,
2.5 pmol of the forward primer and 0.75 pmol of the
reverse-tailed primer, 0.78 pmol of a fluorescent dye-
labeled primer complementary to the tail sequence, 20
μMd N T Pm i x ,a n d0 . 5u n i t so fTaq DNA polymerase
(Qiagen Hot StarTaq, Qiagen Inc, Valencia, CA), with
dH2O to final volume. PCR cycling conditions were 95°
C for 20 minutes, then 40 cycles of the following: 94°C
for 30 seconds, 58°C for 30 seconds, and 72°C for 30 to
60 seconds (depending on product size), and a final
extension of 72°C for 15 minutes. PCR products were
prepared for capillary gel electrophoresis according to
manufacturer’s recommendations and size separated
using the Beckman CEQ 8000 automated DNA-frag-
ment analyzer with fluorescence detection (Beckman
Coulter Inc, Fullerton CA). Genotype data were ana-
lyzed with instrument software, and alleles were manu-
ally verified.
Statistical Analysis
Marker heterozygosity was calculated using the follow-
ing formula: H =1-Σpi
2, where pi is the population fre-
quency of the ith allele, and H is the probability that a
random individual is heterozygous for any two alleles at
a gene locus with allele frequencies, pi [64]. A cut-off of
0.3 was selected for heterozygosity; markers with hetero-
zygosity falling below this cut-off were not considered
informative enough to confidently claim a non-signifi-
cant result for a gene, since less than one third of all
individuals would be expected to be heterozygous at
that locus [64].
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family pedigrees to detect linkage, simulated linkage was
performed with the FASTSLINK program [65-67]. Mul-
tiple parameters were used, including combinations of 3
and 4 equally frequent alleles, 0 and 5% heterogeneity
(proportion of unlinked families) and recombination fre-
quencies of 0.01 and 0.001. Recombination frequencies
were kept very small since the microsatellites tested
were within or very near to the candidate genes. Two
hundred simulations were performed for each set of
parameters, assuming autosomal recessive inheritance.
Parametric two-point linkage analysis was utilized for
Vizsla marker data, with significant evidence for linkage
a LOD (logarithm of odds) score of 3.2 or greater [68].
A LOD score of less than -2.0 was considered to
exclude a locus. Input assumptions were an autosomal
recessive mode of inheritance with 95% penetrance for
the disease genotype, and a disease allele frequency of
0.20; these assumptions were based on previously pub-
lished data concerning IE in this breed [23]. Two-point
LOD scores were calculated using the FASTLINK ver-
sion of MLINK [69-72].
For the GSMD, ESS, and Beagles, the allele frequen-
cies were subjected to a nonparametric chi-square test
for independence (association analysis) [73]. Alleles with
frequencies of less than 10% (minor alleles) were
removed before conducting the chi-square analysis. A
Pearson chi-square p-value of 0.05 was first used as the
level of significance necessary to detect significantly dif-
ferent allele frequencies between affected and unaffected
dogs. Subsequently, a Bonferroni corrected p-value of
0.001, correcting for ~52 tests, was considered evidence
for strong association. Power analyses were not specifi-
cally conducted for these three breeds, as sample size
requirements for canine association studies have not
been precisely defined.
Additional material
Additional file 1: Primer sequences for candidate gene
microsatellites. Sequence information and product sizes are presented
for primers designed for microsatellites examined for each candidate
gene. Bolded genes marked with a * indicate those associated with
human epilepsy, and bolded genes marked with a # indicate those
associated with mouse models of epilepsy. Two of the DNM1 marker
primer pairs, DNM1 Third Set and DNM1 Fifth Set, are taken from the
University of California-Davis Canine Genetic Linkage Map [74], and are
named therein 0945 and 0946, respectively. CFA = canis familiaris
chromosome.
Additional file 2: Candidate gene locations and primer locations. All
pertinent canine chromosomal location information is presented for each
gene and all microsatellites examined for that gene. Bolded genes
marked with a * indicate those associated with human epilepsy, and
bolded genes marked with a # indicate those associated with mouse
models of epilepsy. Two of the DNM1 marker primer pairs, DNM1 Third
Set and DNM1 Fifth Set, are taken from the University of California-Davis
Canine Genetic Linkage Map [74], and are named therein 0945 and 0946,
respectively. ^ Bolded entries in this column indicate microsatellites
located outside the gene itself and further than 1 Mb away (n = 3). Mb
positions given for microsatellites are the first nucleotide of each
microsatellite. Mb positions were taken from Ensembl [75] and the UCSC
Genome Browser [61]. CFA = canis familiaris chromosome.
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